Allan Hildesheim1, Sholom Wacholder2, Gregory Catteau3, Frank Struyf4, Gary Dubin5, Rolando Herrero6. 1. National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics, 9609 Medical Center Drive, Bethesda, MD 20892, United States. Electronic address: hildesha@exchange.nih.gov. 2. National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics, 9609 Medical Center Drive, Bethesda, MD 20892, United States. Electronic address: wacholds@exchange.nih.gov. 3. GlaxoSmithKline Vaccines, Avenue Fleming 20, B-1300 Wavre, Belgium. Electronic address: gregory.x.catteau@gsk.com. 4. GlaxoSmithKline Vaccines, Avenue Fleming 20, B-1300 Wavre, Belgium. Electronic address: frank.struyf@gsk.com. 5. GlaxoSmithKline SA, 2301 Renaissance 22 Boulevard, RN0220, King of Prussia, PA 19406, United States. Electronic address: Gary.O.Dubin@gsk.com. 6. Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Solarium Bldg., Liberia, Costa Rica. Electronic address: HerreroR@iarc.fr.
Abstract
BACKGROUND: A community-based randomized trial was conducted in Costa Rica to evaluate the HPV-16/18 AS04-adjuvanted vaccine (NCT00128661). The primary objective was to evaluate efficacy of the vaccine to prevent cervical intraepithelial neoplasia 2 or more severe disease (CIN2+) associated with incident HPV-16/18 cervical infections. Secondary objectives were to evaluate efficacy against CIN2+ associated with incident cervical infection by any oncogenic HPVs and to evaluate duration of protection against incident cervical infection with HPV-16/18. Vaccine safety and immunogenicity over the 4-year follow-up were also evaluated. METHODS: We randomized (3727 HPV arm; 3739 control arm), vaccinated (HPV-16/18 or Hepatitis A) and followed (median 53.8 months) 7466 healthy women aged 18-25 years. 5312 women (2635 HPV arm; 2677 control arm) were included in the according to protocol analysis for efficacy. The full cohort was evaluated for safety. Immunogenicity was considered on a subset of 354 (HPV-16) and 379 (HPV-18) women. HPV type was assessed by PCR on cervical specimens. Immunogenicity was assessed using ELISA and inhibition enzyme immunoassays. Disease outcomes were histologically confirmed. Vaccine efficacy and 95% confidence intervals (95%CI) were computed. RESULTS:Vaccine efficacy was 89.8% (95% CI: 39.5-99.5; N=11 events total) against HPV-16/18 associated CIN2+, 59.9% (95% CI: 20.7-80.8; N=39 events total) against CIN2+ associated with non-HPV-16/18 oncogenic HPVs and 61.4% (95% CI: 29.5-79.8; N=51 events total) against CIN2+ irrespective of HPV type. The vaccine had an acceptable safety profile and induced robust and long-lasting antibody responses. CONCLUSIONS: Our findings confirm the high efficacy and immunogenicity of the HPV-16/18 vaccine against incident HPV infections and cervical disease associated with HPV-16/18 and other oncogenic HPV types. These results will serve as a benchmark to which we can compare future findings from the ongoing extended follow-up of participants in the Costa Rica trial. TRIAL REGISTRATION: Registered with clinicaltrials.gov: NCT00128661. Published by Elsevier Ltd.
RCT Entities:
BACKGROUND: A community-based randomized trial was conducted in Costa Rica to evaluate the HPV-16/18 AS04-adjuvanted vaccine (NCT00128661). The primary objective was to evaluate efficacy of the vaccine to prevent cervical intraepithelial neoplasia 2 or more severe disease (CIN2+) associated with incident HPV-16/18 cervical infections. Secondary objectives were to evaluate efficacy against CIN2+ associated with incident cervical infection by any oncogenic HPVs and to evaluate duration of protection against incident cervical infection with HPV-16/18. Vaccine safety and immunogenicity over the 4-year follow-up were also evaluated. METHODS: We randomized (3727 HPV arm; 3739 control arm), vaccinated (HPV-16/18 or Hepatitis A) and followed (median 53.8 months) 7466 healthy women aged 18-25 years. 5312 women (2635 HPV arm; 2677 control arm) were included in the according to protocol analysis for efficacy. The full cohort was evaluated for safety. Immunogenicity was considered on a subset of 354 (HPV-16) and 379 (HPV-18) women. HPV type was assessed by PCR on cervical specimens. Immunogenicity was assessed using ELISA and inhibition enzyme immunoassays. Disease outcomes were histologically confirmed. Vaccine efficacy and 95% confidence intervals (95%CI) were computed. RESULTS: Vaccine efficacy was 89.8% (95% CI: 39.5-99.5; N=11 events total) against HPV-16/18 associated CIN2+, 59.9% (95% CI: 20.7-80.8; N=39 events total) against CIN2+ associated with non-HPV-16/18 oncogenic HPVs and 61.4% (95% CI: 29.5-79.8; N=51 events total) against CIN2+ irrespective of HPV type. The vaccine had an acceptable safety profile and induced robust and long-lasting antibody responses. CONCLUSIONS: Our findings confirm the high efficacy and immunogenicity of the HPV-16/18 vaccine against incident HPV infections and cervical disease associated with HPV-16/18 and other oncogenic HPV types. These results will serve as a benchmark to which we can compare future findings from the ongoing extended follow-up of participants in the Costa Rica trial. TRIAL REGISTRATION: Registered with clinicaltrials.gov: NCT00128661. Published by Elsevier Ltd.
Entities:
Keywords:
Cervical neoplasia; Clinical trial; Human papillomaviruses; Prevention; Vaccination
Authors: Cosette M Wheeler; Xavier Castellsagué; Suzanne M Garland; Anne Szarewski; Jorma Paavonen; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Dan Apter; Henry Kitchener; Júlio C Teixeira; S Rachel Skinner; Unnop Jaisamrarn; Genara Limson; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Diane M Harper; Warner Huh; Karin Hardt; Toufik Zahaf; Dominique Descamps; Frank Struyf; Gary Dubin; Matti Lehtinen Journal: Lancet Oncol Date: 2011-11-08 Impact factor: 41.316
Authors: Cecilia M Roteli-Martins; Paulo Naud; Paola De Borba; Julio C Teixeira; Newton S De Carvalho; Toufik Zahaf; Nervo Sanchez; Brecht Geeraerts; Dominique Descamps Journal: Hum Vaccin Immunother Date: 2012-02-13 Impact factor: 3.452
Authors: Rolando Herrero; Sholom Wacholder; Ana C Rodríguez; Diane Solomon; Paula González; Aimee R Kreimer; Carolina Porras; John Schussler; Silvia Jiménez; Mark E Sherman; Wim Quint; John T Schiller; Douglas R Lowy; Mark Schiffman; Allan Hildesheim Journal: Cancer Discov Date: 2011-09-09 Impact factor: 39.397
Authors: Mahboobeh Safaeian; Troy J Kemp; David Yuanji Pan; Carolina Porras; Ana Cecilia Rodriguez; Mark Schiffman; Bernal Cortes; Hormuzd Katki; Sholom Wacholder; John T Schiller; Paula Gonzalez; Kerri Penrose; Douglas R Lowy; Wim Quint; Leen-Jan van Doorn; Rolando Herrero; Allan Hildesheim; Ligia A Pinto Journal: Hum Vaccin Immunother Date: 2013-04-09 Impact factor: 3.452
Authors: Aimée R Kreimer; Ana Cecilia Rodriguez; Allan Hildesheim; Rolando Herrero; Carolina Porras; Mark Schiffman; Paula González; Diane Solomon; Silvia Jiménez; John T Schiller; Douglas R Lowy; Wim Quint; Mark E Sherman; John Schussler; Sholom Wacholder Journal: J Natl Cancer Inst Date: 2011-09-09 Impact factor: 13.506
Authors: Rolando Herrero; Wim Quint; Allan Hildesheim; Paula Gonzalez; Linda Struijk; Hormuzd A Katki; Carolina Porras; Mark Schiffman; Ana Cecilia Rodriguez; Diane Solomon; Silvia Jimenez; John T Schiller; Douglas R Lowy; Leen-Jan van Doorn; Sholom Wacholder; Aimée R Kreimer Journal: PLoS One Date: 2013-07-17 Impact factor: 3.240
Authors: Sabrina H Tsang; Partha Basu; Noemi Bender; Rolando Herrero; Troy J Kemp; Aimée R Kreimer; Martin Müller; Gitika Panicker; Michael Pawlita; Ligia A Pinto; Joshua N Sampson; Rengaswamy Sankaranarayanan; John Schussler; Peter Sehr; Monica S Sierra; Elizabeth R Unger; Tim Waterboer; Allan Hildesheim Journal: Vaccine Date: 2020-07-24 Impact factor: 3.641
Authors: Daniel C Beachler; Aimée R Kreimer; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Ana Cecilia Rodriguez; Douglas R Lowy; Carolina Porras; John T Schiller; Wim Quint; Silvia Jimenez; Mahboobeh Safaeian; Linda Struijk; John Schussler; Allan Hildesheim; Paula Gonzalez Journal: J Natl Cancer Inst Date: 2015-10-14 Impact factor: 13.506
Authors: Paula Gonzalez; Allan Hildesheim; Rolando Herrero; Hormuzd Katki; Sholom Wacholder; Carolina Porras; Mahboobeh Safaeian; Silvia Jimenez; Teresa M Darragh; Bernal Cortes; Brian Befano; Mark Schiffman; Loreto Carvajal; Joel Palefsky; John Schiller; Rebeca Ocampo; John Schussler; Douglas Lowy; Diego Guillen; Mark H Stoler; Wim Quint; Jorge Morales; Carlos Avila; Ana Cecilia Rodriguez; Aimée R Kreimer Journal: Vaccine Date: 2015-03-18 Impact factor: 3.641
Authors: Richard Gilson; Diarmuid Nugent; Kate Bennett; Caroline J Doré; Macey L Murray; Jade Meadows; Lewis J Haddow; Charles Lacey; Frank Sandmann; Mark Jit; Kate Soldan; Michelle Tetlow; Emilia Caverly; Mayura Nathan; Andrew J Copas Journal: Health Technol Assess Date: 2020-09 Impact factor: 4.014
Authors: Lisa Mirabello; Meredith Yeager; Kai Yu; Gary M Clifford; Yanzi Xiao; Bin Zhu; Michael Cullen; Joseph F Boland; Nicolas Wentzensen; Chase W Nelson; Tina Raine-Bennett; Zigui Chen; Sara Bass; Lei Song; Qi Yang; Mia Steinberg; Laurie Burdett; Michael Dean; David Roberson; Jason Mitchell; Thomas Lorey; Silvia Franceschi; Philip E Castle; Joan Walker; Rosemary Zuna; Aimée R Kreimer; Daniel C Beachler; Allan Hildesheim; Paula Gonzalez; Carolina Porras; Robert D Burk; Mark Schiffman Journal: Cell Date: 2017-09-07 Impact factor: 41.582
Authors: Joshua N Sampson; Allan Hildesheim; Rolando Herrero; Paula Gonzalez; Aimee R Kreimer; Mitchell H Gail Journal: Contemp Clin Trials Date: 2018-02-21 Impact factor: 2.226
Authors: Ariana Harari; Zigui Chen; Ana Cecilia Rodríguez; Allan Hildesheim; Carolina Porras; Rolando Herrero; Sholom Wacholder; Orestis A Panagiotou; Brian Befano; Robert D Burk; Mark Schiffman Journal: J Infect Dis Date: 2015-10-30 Impact factor: 5.226